# A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

> **NCT01343277** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 579 (actual)

## Conditions studied

- Advanced Liposarcoma or Leiomyosarcoma

## Interventions

- **DRUG:** Trabectedin
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT01343277
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2015-01
- **Final completion:** 2016-04
- **Target enrollment:** 579 (ACTUAL)
- **Last updated:** 2016-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01343277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01343277, "A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01343277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*